NATIONAL CENTERS FOR NEUROFIBROMATOSIS RESEARCH
RELEASE DATE: November 5, 2003
PA NUMBER: PAR-04-018
EXPIRATION DATE: February 1, 2007, unless reissued
Department of Health and Human Services (DHHS)
PARTICIPATING ORGANIZATION:
National Institutes of Health (NIH)
(http://www.nih.gov)
COMPONENTS OF PARTICIPATING ORGANIZATION:
National Institute of Neurological Disorders and Stroke (NINDS)
(http://www.ninds.nih.gov)
National Institute of Deafness and Other Communication Disorders (NIDCD)
(http://www.nidcd.nih.gov)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBERS: 93.853 (NINDS), 93.173 (NIDCD)
THIS PA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this PA
o Research Objectives
o Mechanism(s) of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS PA
The National Institute of Neurological Disorders and Stroke (NINDS) and
the National Institute of Deafness and Other Communication Disorders
(NIDCD) invite qualified investigators to submit grant applications for
the establishment of National Centers for Neurofibromatosis Research.
Recent discoveries have created important opportunities for basic,
translational, and clinical research on the neurofibromatoses. The
purpose of this Program Announcement (PA) is to encourage the formation
and development of research centers that can capitalize on these
opportunities, and ultimately develop therapeutic interventions for
neurofibromatosis patients. These centers are intended to provide
focused expertise and resources, and establish a multi-disciplinary
environment that will accelerate research progress.
RESEARCH OBJECTIVES
Background
The neurofibromatoses (NF) are autosomal dominant genetic disorders that
cause tumors to grow along peripheral nerves. NF also often affects the
development of other tissues (including bones, skin, heart, blood, and
brain) and causes learning disabilities in approximately one-third of
patients. There are three distinct forms of NF - NF1, NF2, and the
recently identified subtype schwannomatosis. Patients with these
disorders experience a wide range of symptoms, which range from mild to
devastating.
Over a decade ago, investigators identified the genes that cause NF1 and
NF2 (neurofibromin and merlin/schwannomin respectively) and began to
characterize their protein products. NF has served as an important
paradigm for understanding how mutations in single genes can affect the
development of multiple tissues. A great deal of information is now
available regarding the functions of the NF1 and NF2 gene products, as
well as about the signaling pathways in which they participate. These
advances in basic research are providing hope that rational therapeutics
will be developed to block the aberrant cell proliferation and other
abnormalities associated with these diseases. In addition,
sophisticated cell and animal models now exist that can be used to test
candidate therapeutics.
The goal of NF research is the development of more effective therapies
for patients with these disorders. Current treatment modalities, such as
surgery and radiation, are at best designed to ameliorate specific
symptoms. Developing more effective pharmaceutical or biological
interventions will require further basic research, pre-clinical therapy
development, and clinical studies and trials. Much of this research
will require centralized resources and interdisciplinary collaborations.
For example, testing candidate therapeutics can be done more efficiently
in an environment where the appropriate cell and animal models are
assembled, and screening technologies are optimized. Centralized tissue
repositories, clinical databases, and other resources will greatly
facilitate genetic and epidemiological studies. Effective clinical
trials require both infrastructure and sufficient numbers of well-
characterized patients. Interaction between basic scientists and
clinicians will also be critical for translating research discoveries
into interventions that can be tested in the clinic.
Scope
NF centers are intended to provide an interdisciplinary, interactive
environment that will accelerate research progress and permit studies
that could not be done as effectively in individual laboratories.
Proposals should include a minimum of three research projects, which can
be basic, translational, or clinical in focus. However, at least one
project in each center application should focus specifically on
preclinical therapy development or clinical research, and all centers
should be designed to enhance progress towards the goal of treating NF.
Projects should be designed to take advantage of the interactive,
centralized facilities provided by the proposed center. In addition, a
strong case must be made that the individual projects are synergistic in
nature. Finally, every center should include at least one project
focusing on NF1, the most common of the three forms of NF.
Proposed research projects should relate directly to the etiology,
pathogenesis or treatment of NF. Examples of possible projects include:
o Molecular and cell biological studies of NF1, NF2, or schwannomatosis
that will be accelerated by the centralized availability of research and
clinical expertise, patient DNAs and tissues, or other resources.
o Investigation of the pathogenesis of neurofibromas, gliomas,
malignant peripheral nerve sheath tumors, skeletal and cardiovascular
abnormalities, learning disabilities, and other manifestations of NF.
o High-throughput preclinical screening of candidate NF therapeutics.
o Development of improved cell and animal models for preclinical
screening.
o Genotype-phenotype studies of NF patients.
o Identification of NF modifier genes and analysis of their effects on
patient phenotype.
o Natural History studies, particularly those that will guide
therapeutic interventions or establish a baseline for future clinical
trials.
o Phase I or II Clinical Trials of potential therapeutic interventions
for NF.
o Development of improved and standardized methods for assessing
outcome in NF clinical trials and clinical research (e.g. measurement
tools for tumors, NF-specific microarrays, cognitive measures).
In addition to describing the proposed research projects, applicants
must explain how establishing a research center will either accelerate
research progress or permit research that would be difficult or
impossible in an individual laboratory. Such justification could, for
example, include how a center will permit:
o Centralization of resources (e.g. tissues, DNAs, genotypic or
phenotypic information derived from patients) required for the proposed
research projects.
o More efficient preclinical testing of potential therapeutics.
o Pooling of patient populations, without which a specific clinical
study or trial could not be achieved.
o Interaction between basic researchers and clinicians.
o Training of potential NF researchers directly involved in center
activities or visiting the center from other sites.
Applicants can propose the establishment of core facilities necessary
for the proposed research. For example, cores designed to collect
tissue or DNA samples, store genotypic or phenotypic information,
facilitate clinical studies or trials, or coordinate administrative
functions can be included within each center proposal. Applicants must
describe in detail why each core facility is required for the research
described in the application.
MECHANISM OF SUPPORT
The mechanism of support for this solicitation will be the Research
Center Grant (P50). Responsibility for planning, direction, and
execution of the proposed research centers will rest solely with the
applicant. Because the nature and scope of the research proposed in
response to this PA may vary, it is anticipated that the size of the
award may also vary.
NINDS P50 grants are generally limited to $1 million dollars per year
direct costs for five years. However, high quality patient-oriented
research requires resources devoted to training personnel, ensuring
appropriate inclusion and follow-up of subjects, monitoring patient
safety, and coordinating activities among participating sites (see
http://www.nih.gov/news/crp/97report/execsum.htm). Therefore, NINDS
recently published a notice raising the budget ceiling for specific
solicited P50 applications to $1.5 million per year direct costs (see
http://grants.nih.gov/grants/guide/notice-files/NOT-NS-03-020.html).
This increased ceiling will also apply to center applications received
through this PA that have significant clinical components. Applicants
requesting additional funds must explain clearly why they are required
for the proposed clinical studies.
Any future unsolicited competing continuation applications based on this
project will compete with all NIH investigator-initiated applications
and be reviewed according to the customary peer review procedures.
This PA uses just-in-time concepts. Investigators seeking to carry out
pilot studies of therapies in preparation for a clinical trial should
apply under the auspices of the Preliminary Investigations Leading to
Optimal Trials in Neurology program announcement PAR-03-174. Since such
applications must conform to the intent of both program announcements,
including the additional review criteria of PAR-03-174
(http://grants.nih.gov/grants/guide/pa-files/PAR-03-174.html), potential
applicants are strongly encouraged to contact NINDS program staff for
guidance. Close collaboration and integration between research center
activities and clinical trials is encouraged.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges,
hospitals, and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic institutions/organizations
o Foreign institutions are not eligible to apply
o Faith-based or community based organizations
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to
carry out the proposed research is invited to work with their
institution to develop an application for support. Individuals from
underrepresented racial and ethnic groups as well as individuals with
disabilities are always encouraged to apply for NIH programs.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this PA and welcome the opportunity
to answer questions from potential applicants. Inquiries may fall into
three areas: scientific/research, peer review, and financial or grants
management issues:
Direct your questions about scientific/research issues to:
Robert Finkelstein, Ph.D.
Neurogenetics Cluster
National Institute of Neurological Disorders and Stroke
Neuroscience Center, RM 2143
6001 Executive Blvd MSC 9525
Bethesda, MD 20892-9525
Phone: 301-496-5745
FAX: 301-402-1501
Email: rf45c@nih.gov
Amy M. Donahue, Ph.D.
Division of Scientific Programs
National Institute on Deafness and Other Communication Disorders
6120 Executive Boulevard RM 400C, MSC-7180
Bethesda, MD 20892-7180
Phone: 301-402-3458
FAX: 301-402-6251
Email: donahuea@nidcd.nih.gov
Direct your questions about peer review issues to:
Alan Willard, Ph.D.
Chief, Scientific Review Branch
National Institute of Neurological Disorders and Stroke
Neuroscience Center, RM 3208
6001 Executive Blvd MSC 9529
Bethesda, MD 20892-9529
Phone: 301-496-9223
FAX: 301-402-0182
Email: aw135y@nih.gov
Direct your questions about financial or grants management matters to:
Kathleen Howe
Grants Management Branch
National Institute of Neurological Disorders and Stroke
6001 Executive Boulevard, Room 3266
Bethesda, MD 20892
Phone: (301) 496-9231
FAX: (301) 402-0219
Email: kh52x@nih.gov
Sara Stone
Division of Extramural Activities
National Institute on Deafness and Other Communication Disorders
6120 Executive Boulevard, Room 400B, MSC-7180
Bethesda, MD 20892-7180
Telephone: 301-402-0909
FAX: 301-402-1758
Email: stones@nidcd.nih.gov
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant
application instructions and forms (rev. 5/2001). Applications must
have a Dun and Bradstreet (D&B) Data Universal Numbering System (DUNS)
number as the Universal Identifier when applying for Federal grants or
cooperative agreements. The DUNS number can be obtained by calling
(866) 705-5711 or through the web site at
http://www.dunandbradstreet.com/. The DUNS number should be entered on
line 11 of the face page of the PHS 398 form. The PHS 398 is available
at http://grants.nih.gov/grants/funding/phs398/phs398.html in an
interactive format. For further assistance contact GrantsInfo,
Telephone (301) 710-0267, Email: GrantsInfo@nih.gov.
The title and number of this PAR must be typed in line 2 of the face
page of the application form and the YES box must be checked.
APPLICATION RECEIPT DATES: Applications submitted in response to this
program announcement will be accepted at the standard application
deadlines, which are available at
http://grants.nih.gov/grants/dates.htm. Application deadlines are also
indicated in the PHS 398 application kit.
SPECIFIC INSTRUCTIONS FOR APPLICATIONS REQUESTING $500,000 OR MORE PER
YEAR: Applications requesting $500,000 or more in direct costs for any
year must include a cover letter identifying the NIH staff member within
one of NIH institutes or centers who has agreed to accept assignment of
the application.
Applicants requesting more than $500,000 must carry out the following
steps:
1) Contact the IC program staff at least 6 weeks before submitting the
application, i.e., as you are developing plans for the study;
2) Obtain agreement from the IC staff that the IC will accept your
application for consideration for award; and,
3) Identify, in a cover letter sent with the application, the staff
member and IC who agreed to accept assignment of the application.
This policy applies to all investigator-initiated new (type 1),
competing continuation (type 2), competing supplement, or any amended
or revised version of these grant application types. Additional
information on this policy is available in the NIH Guide for Grants and
Contracts, October 19, 2001 at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten
original of the application, including the Checklist, and three signed,
photocopies, in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application must
be sent to:
Alan Willard, Ph.D.
Chief, Scientific Review Branch
National Institute of Neurological Disorders and Stroke
Neuroscience Center, RM 3208
6001 Executive Blvd MSC 9529
Bethesda, MD 20892-9529
Phone: 301-496-9223
FAX: 301-402-0182
Email: aw135y@nih.gov
APPLICATION PROCESSING: Applications must be received by or mailed on
or before the receipt dates described at
http://grants.nih.gov/grants/funding/submissionschedule.htm. The CSR
will not accept any application in response to this PA that is
essentially the same as one currently pending initial review unless the
applicant withdraws the pending application. The CSR will not accept
any application that is essentially the same as one already reviewed.
This does not preclude the submission of a substantial revision of an
application already reviewed, but such application must include an
Introduction addressing the previous critique.
The NINDS Guidelines for the development of Program Project and Center
Applications should be followed when preparing the application. They
are available on the NINDS home page at:
http://www.ninds.nih.gov/index.htm.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and
funding assignment within 8 weeks.
PEER REVIEW PROCESS
Applications submitted for this PA will be assigned on the basis of
established PHS referral guidelines. An appropriate scientific review
group convened by NINDS in accordance with the standard NIH peer review
procedures http://www.csr.nih.gov/refrev.htm) will evaluate
applications for scientific and technical merit.
As part of the initial merit review, all applications will:
o Undergo a selection process in which only those applications deemed
to have the highest scientific merit, generally the top half of the
applications under review, will be discussed and assigned a priority
score.
o Receive a written critique
o Receive a second level review by an appropriate National Advisory
Council or Board.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health.
In the written comments, reviewers will be asked to discuss the
following aspects of your application in order to judge the likelihood
that the proposed research will have a substantial impact on the
pursuit of these goals. The scientific review group will address and
consider each of these criteria in assigning your application's overall
score, weighting them as appropriate for each application.
o Significance
o Approach
o Innovation
o Investigator
o Environment
The application does not need to be strong in all categories to be
judged likely to have major scientific impact and thus deserve a high
priority score. For example, you may propose to carry out important
work that by its nature is not innovative, but is essential to move a
field forward.
(1) SIGNIFICANCE: Does your study address an important problem? If the
aims of your application are achieved, how do they advance scientific
knowledge? What will be the effect of these studies on the concepts or
methods that drive this field?
(2) APPROACH: Are the conceptual framework, design, methods, and
analyses adequately developed, well integrated, and appropriate to the
aims of the project? Do you acknowledge potential problem areas and
consider alternative tactics?
(3) INNOVATION: Does your project employ novel concepts, approaches or
methods? Are the aims original and innovative? Does your project
challenge existing paradigms or develop new methodologies or
technologies?
(4) INVESTIGATOR: Are you appropriately trained and well suited to
carry out this work? Is the work proposed appropriate to your
experience level as the principal investigator and to that of other
researchers (if any)?
(5) ENVIRONMENT: Does the scientific environment in which your work
will be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, your
application will also be reviewed with respect to the following:
INTEGRATION AND COLLABORATION: The ability of the proposed Center
to promote integration across research projects and collaboration across
laboratories including basic, translational, and clinical approaches.
Activities in each project should inform and advance the others and the
proposed collaborative activities should provide synergy to the proposed
Center.
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of
human subjects and protections from research risk relating to their
participation in the proposed research will be assessed. (See criteria
included in the section on Federal Citations, below).
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
o INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy
of plans to include subjects from both genders, all racial and ethnic
groups (and subgroups), and children as appropriate for the scientific
goals of the research. Plans for the recruitment and retention of
subjects will also be evaluated. (See
Inclusion Criteria included in the section on Federal Citations, below)
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals
are to be used in the project, the five items described under Section f
of the PHS 398 research grant application instructions (rev. 5/2001)
will be assessed.
ADDITIONAL REVIEW CONSIDERATIONS
SHARING RESEARCH DATA: Applicants requesting more than $500,000 in
direct costs in any year of the proposed research are expected to
include a data sharing plan in their application. The reasonableness of
the data sharing plan or the rationale for not sharing research data
will be assessed by the reviewers. However, reviewers will not factor
the proposed data sharing plan into the determination of scientific
merit or priority score.
BUDGET: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research.
AWARD CRITERIA
Applications submitted in response to a PA will compete for available
funds with all other recommended applications. The following will be
considered in making funding decisions:
o Scientific merit of the proposed project as determined by peer review
o Availability of funds
o Relevance to program priorities
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated
with reference to the risks to the subjects, the adequacy of protection
against these risks, the potential benefits of the research to the
subjects and others, and the importance of the knowledge gained or to be
gained. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
DATA AND SAFETY MONITORING PLAN: Data and safety monitoring is required
for all types of clinical trials, including physiologic, toxicity, and
dose-finding studies (phase I); efficacy studies (phase II), efficacy,
effectiveness and comparative trials (phase III). The establishment of
data and safety monitoring boards (DSMBs) is required for multi-site
clinical trials involving interventions that entail potential risk to
the participants. (NIH Policy for Data and Safety Monitoring, NIH Guide
for Grants and Contracts, June 12, 1998:
http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
SHARING RESEARCH DATA: Starting with the October 1, 2003 receipt date,
investigators submitting an NIH application seeking $500,000 or more in
direct costs in any single year are expected to include a plan for data
sharing or state why this is not possible.
http://grants.nih.gov/grants/policy/data_sharing Investigators should
seek guidance from their institutions, on issues related to
institutional policies, local IRB rules, as well as local, state and
Federal laws and regulations, including the Privacy Rule. Reviewers will
consider the data sharing plan but will not factor the plan into the
determination of the scientific merit or the priority score.
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the
policy of the NIH that women and members of minority groups and their
sub-populations must be included in all NIH-supported clinical research
projects unless a clear and compelling justification is provided
indicating that inclusion is inappropriate with respect to the health
of the subjects or the purpose of the research. This policy results
from the NIH Revitalization Act of 1993 (Section 492B of Public Law
103-43).
All investigators proposing clinical research should read the AMENDMENT
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in
Clinical Research - Amended, October, 2001," published in the NIH Guide
for Grants and Contracts on October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition
of clinical research; updated racial and ethnic categories in
compliance with the new OMB standards; clarification of language
governing NIH-defined Phase III clinical trials consistent with the new
PHS Form 398; and updated roles and responsibilities of NIH staff and
the extramural community. The policy continues to require for all NIH-
defined Phase III clinical trials that: a) all applications or
proposals and/or protocols must provide a description of plans to
conduct analyses, as appropriate, to address differences by sex/gender
and/or racial/ethnic groups, including subgroups if applicable; and b)
investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN
SUBJECTS: The NIH maintains a policy that children (i.e., individuals
under the age of 21) must be included in all human subjects research,
conducted or supported by the NIH, unless there are scientific and
ethical reasons not to include them. This policy applies to all initial
(Type 1) applications submitted for receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should
read the "NIH Policy and Guidelines" on the inclusion of children as
participants in research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject
participants for all investigators submitting NIH proposals for
research involving human subjects. You will find this policy
announcement in the NIH Guide for Grants and Contracts Announcement,
dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of
research on hESCs can be found at
http://stemcells.nih.gov/index.asp and at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html.
Only research using hESC lines that are registered in the NIH Human
Embryonic Stem Cell Registry will be eligible for Federal funding (see
http://escr.nih.gov). It is the responsibility of the applicant to
provide, in the project description and elsewhere in the application as
appropriate, the official NIH identifier(s) for the hESC line(s)to be
used in the proposed research. Applications that do not provide this
information will be returned without review.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT:
The Office of Management and Budget (OMB) Circular A-110 has been
revised to provide public access to research data through the Freedom
of Information Act (FOIA) under some circumstances. Data that are (1)
first produced in a project that is supported in whole or in part with
Federal funds and (2) cited publicly and officially by a Federal agency
in support of an action that has the force and effect of law (i.e., a
regulation) may be accessed through FOIA. It is important for
applicants to understand the basic scope of this amendment. NIH has
provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application
should include a description of the archiving plan in the study design
and include information about this in the budget justification section
of the application. In addition, applicants should think about how to
structure informed consent statements and other human subjects
procedures given the potential for wider use of data collected under
this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION:
The Department of Health and Human Services (DHHS) issued final
modification to the Standards for Privacy of Individually Identifiable
Health Information , the Privacy Rule, on August 14, 2002. The
Privacy Rule is a federal regulation under the Health Insurance
Portability and Accountability Act (HIPAA) of 1996 that governs the
protection of individually identifiable health information, and is
administered and enforced by the DHHS Office for Civil Rights (OCR).
Those who must comply with the Privacy Rule (classified under the Rule
as covered entities ) must do so by April 14, 2003 (with the exception
of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule
reside with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule,
including a complete Regulation Text and a set of decision tools on Am
I a covered entity? Information on the impact of the HIPAA Privacy
Rule on NIH processes involving the review, funding, and progress
monitoring of grants, cooperative agreements, and research contracts can
be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and
proposals for NIH funding must be self-contained within specified page
limitations. Unless otherwise specified in an NIH solicitation,
Internet addresses (URLs) should not be used to provide information
necessary to the review because reviewers are under no obligation to
view the Internet sites. Furthermore, we caution reviewers that their
anonymity may be compromised when they directly access an Internet
site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of
"Healthy People 2010," a PHS-led national activity for setting priority
areas. This PA is related to one or more of the priority areas.
Potential applicants may obtain a copy of "Healthy People 2010" at
http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject
to the intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review. Awards are made under the authorization
of Sections 301 and 405 of the Public Health Service Act as amended (42
USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR
Parts 74 and 92. All awards are subject to the terms and conditions,
cost principles, and other considerations described in the NIH Grants
Policy Statement. The NIH Grants Policy Statement can be found at
http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in
which regular or routine education, library, day care, health care, or
early childhood development services are provided to children. This is
consistent with the PHS mission to protect and advance the physical and
mental health of the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|